Ollin Biosciences
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD
$330MSeries B
Role not disclosedMC
Mubadala Capital
Activity from announced rounds
Activity in this selectionsymbolic-capital-f3f73206
- Rounds participated in
- 3
- Confirmed lead rounds
- — 3 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $403.5M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionAlloy Therapeutics
Provides AI-powered platforms and integrated services for drug discovery and development
$40MSeries E
Role not disclosedJuvena Therapeutics
Develops regenerative biologics to restore tissue function
$33.5MSeries B
Role not disclosed